Lyfebulb, and Arena Pharmaceuticals, a company focused on developing innovative therapeutics for immune-mediated conditions, announce the ten patient entrepreneurs selected as finalists for the 2021 Imagining Life Without Limits – An Inflammatory Bowel Disease Innovation Challenge.
Finalists will compete for a $25,000 award |
| [29-June-2021] |
| NEW YORK, June 29, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform and innovation accelerator that connects patients with one another and with industry to support user-driven innovation, and Arena Pharmaceuticals, Inc., a company focused on developing innovative therapeutics for immune-mediated conditions, announce the ten patient entrepreneurs selected as finalists for the 2021 Imagining Life Without Limits – An Inflammatory Bowel Disease Innovation Challenge.
Lyfebulb and Arena Pharmaceuticals Announce the Finalists for the 2021 Inflammatory Bowel Disease Innovation Challenge Lyfebulb and Arena Pharmaceuticals’ goal with this Innovation Challenge is to identify new and meaningful solutions that help patients, support partners, and all those affected by inflammatory bowel disease (IBD) to better manage their health, navigate daily life, and improve overall quality of life. The ten finalists selected to compete at the Challenge were chosen based on the potential of their innovative ventures to address these issues as well as their personal stories that sparked the launch of their companies. “IBD comprises a set of chronic diseases that affect each individual throughout the day, from diet choices to exercise to therapeutic options. Consequentially, monitoring biometrics and more qualitative personal metrics may help in detecting flare-ups early or even prevent some of the comorbidities associated with the condition,” stated Karin Hehenberger, MD, PhD, CEO of Lyfebulb. “These innovators have each taken their own path to providing new solutions that address the problems faced by IBD patients – with the goal of improving overall outcomes for patients. We look forward to bringing everyone together at the summit to work toward our shared goal of reducing the burden of living with IBD.” The finalists will pitch their companies’ solutions to an expert panel of judges comprised of leaders from the healthcare, business, and patient advocacy fields on September 10, 2021. The jury will ultimately select one winner to be awarded a $25,000 monetary grant to further the growth of their company. The judging panel will include:
“Arena values bold ideas, relentless thinking, and continuous innovation,” said Lopa Desai, SVP, Head of Global Commercial Operations & Access, Arena Pharmaceuticals. “We are pleased to see the finalists approach the Innovation Challenge with creativity and tenacity to advance ideas with the potential to improve the lives of patients living with IBD.” Beyond the pitch competition, the Challenge will provide opportunities for the finalists and participating guests to exchange ideas and insights about how to further advance patient innovation in the IBD community and impact change. To learn more about the Challenge, please visit: Lyfebulb.com. About the Lyfebulb and Arena Partnership About Lyfebulb About Arena Pharmaceuticals For more information: Lyfebulb Contact: Arena Contact:
SOURCE Lyfebulb |
View original content to download multimedia:
